NEURO3 THERAPEUTICS
Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.
NEURO3 THERAPEUTICS
Industry:
Medical Therapeutics
Founded:
2021-06-25
Address:
Hong Kong, Hong Kong Island, Hong Kong
Country:
Hong Kong
Status:
Active
Total Funding:
10 M USD
Similar Organizations
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Seed Round - Neuro3 Therapeutics
More informations about "Neuro3 Therapeutics"
Neuro3 Therapeutics acquires exclusive worldwide rights to
May 8, 2023 Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) โฆSee details»
Neuro3 Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Explore Neuro3 Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news, Disease Domain:Nervous System Diseases, Technology โฆSee details»
Neuro3 Therapeutics - Funding, Financials, Valuation & Investors
Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. โฆSee details»
Neuro3 Therapeutics Ltd. - Drug pipelines, Patents, Clinical
May 8, 2025 Explore Neuro3 Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 2 news, Disease Domain:Nervous System Diseases, Endocrinology and โฆSee details»
Neuro3 Therapeutics - LifeScienceHistory.com
Neuro3 Therapeutics is an innovation-driven, CNS focused biopharmaceutical company pursuing a pipeline of innovative therapeutic molecules to address neuroexcitatory and โฆSee details»
Neuro3 Therapeutics Ltd. (Neuro3 Therapeutics Ltd.) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
May 7, 2025 CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development โฆSee details»
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to โฆ
May 8, 2023 Neuro3 Therapeutics is an innovation-driven, CNS focused biopharmaceutical company pursuing a pipeline of innovative therapeutic molecules to address neuroexcitatory โฆSee details»
Neuro3 Therapeutics Limited | Hong Kong Companies Directory
Jun 25, 2021 Neuro3 Therapeutics Limited was incorporated on 25-JUN-2021 as a Private company limited by shares registered in Hong Kong. The date of annual examination for this โฆSee details»
Seed Round - Neuro3 Therapeutics - 2025-03-06 - Crunchbase
Mar 6, 2025 Organization Name . Neuro3 Therapeutics . Announced Date Mar 6, 2025; Funding Type Seed; Funding Stage Seed; Money Raised . obfuscated. obfuscated. Pre-Money โฆSee details»
Neuro3 gets rights to KCNQ2 activator development programmes
May 9, 2023 Neuro3 Therapeutics will receive global licences for intellectual property that cover two clinical stage and one pre-clinical stage KCNQ2 activator programmes. Go deeper with โฆSee details»
Neuro3 Therapeutics Acquires Rights for KCNQ2 Activators
May 8, 2023 Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) โฆSee details»
Neuro3 Therapeutics - Updates, News, Events, Signals & Triggers
Neuro3 Therapeutics may be growing as evidenced by its recent acquisition of exclusive worldwide rights to develop and commercialize clinical stage Kcnq2 activators from Lundbeck. โฆSee details»
ไธๆๅป่ฏ๏ผ่ๅท๏ผๆ้ๅ ฌๅธNEURO3 THERAPEUTICS.INC
May 8, 2023 ไธๆๅป่ฏ๏ผ่ๅท๏ผๆ้ๅ ฌๅธNEURO3 THERAPEUTICS.INC Media Room. Latest News; Latest News Time All; 2023; Neuro3 Therapeutics Acquires Exclusive Worldwide Rights โฆSee details»
Neuro3 Therapeutics obtains global rights for KCNQ2 activators โฆ
May 9, 2023 Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) โฆSee details»
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to
May 8, 2023 CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development โฆSee details»
Tiny CNS biotech gets hands on Lundbeck drug candidates
May 8, 2023 Lundbeck is out-licensing three candidates to Neuro3 Therapeutics, a two-year-old biotech based in Cambridge โ and giving itself an option to license back those rights in โฆSee details»
Neuro3 therapeutics acquires exclusive worldwide rights from โฆ
May 8, 2023 Read more: Lundbeck and Alloy Therapeutics collaborate. Under the agreement, Neuro3 will receive a worldwide license for intellectual property covering two clinical stage and โฆSee details»
Neuro3 Therapeutics Acquires Exclusive ... - American Biotech News
May 8, 2023 CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ โ Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development โฆSee details»
Lundbeck sells rights to three development programs - MedWatch
May 8, 2023 Neuro3 Therapeutics acquires licenses to some programs of the Danish company, which however has โan option to exclusively license back the rights in certain territories.โ โฆSee details»
Patritumab deruxtecan in leptomeningeal metastatic disease of โฆ
1 day ago Leptomeningeal metastatic disease (LMD) is a severe complication of solid cancers with poor outcomes and limited treatment options. The antibodyโdrug conjugate patritumab โฆSee details»